Abstract 773P
Background
Homologous Recombination Deficiency (HRD) is assessed by detection of mutations in BRCA1/2 genes (BRCAm) and/or genomic instability score (GIS+). In ovarian cancer, HRD has become an important biomarker to stratify patients for appropriate clinical management and treatment. Myriad myChoice CDX Plus is currently the gold standard for assessing HRD on tumor samples. There is an increasing interest in transitioning into inhouse HRD assays that fulfill analytical concordance and, also, demonstrate clinical validation. Sophia DDM Dx HRD solution is one of the alternatives, which has reached an overall percent agreement of 93% with Myriad, demonstrating also clinical validation in PAOLA-1 trial. In this study, we present the real-world results of HRD testing in Spain.
Methods
Phase 1 (Apr2021-Jun22), consisted in the analysis of 1322 cases from 90 centers, using Myriad myChoice. Phase 2 (Jul2022-Dec22) included 1333 cases from 135 centers, analyzed with Sophia HRD solution in 4 academic centers, after an internal validation.
Results
Phase 1 reported 47% BRCAwt/GIS-, 24% BRCAwt/GIS+, 14% BRCAm (BRCAm/GIS- y BRCAm/GIS+), and 15% inconclusive cases using myChoice. In phase 2, Sophia HRD identified 47% BRCAwt GIS-, 25% BRCAwt/GIS+, 15% BRCAm, and 13% inconclusive cases. The distribution of HRP (range 42.4-50%) and HRD (range 35.7- 40.7%) cases was similar among the reference centers. In addition to GIS and BRCA1/2, Sophia reported CCNE1 amplification (5.3%), as well as mutations in BRIP1 (2.4%), RAD51C (1.1%), RAD51D (1.2%) and PALB2 (1.9%). As expected, CCNE1 amplification was more frequent in HRP (86.5%) than HRD (13.5%).
Conclusions
The results obtained from a cohort of 2655 ovarian cancer samples by two different methods, Myriad myChoice and Sophia HRD, confirm the analytical concordance between HRD assays. Percentages of BRCAwt/GIS-, BRCAwt/GIS+, BRCAm, and invalid cases were almost identical. In conclusion, Sophia DDMTM Dx HRD solution shows a high interlaboratory agreement, providing clinically relevant molecular information, and improving the interaction between referral and reference centers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Federico Rojo.
Funding
AstraZeneca.
Disclosure
M. Orellana: Financial Interests, Personal, Member: AstraZeneca. M. Lencina: Financial Interests, Personal, Other: AstraZeneca. X. Matias-Guiu: Financial Interests, Personal, Advisory Board: AstraZeneca, Amgen, Lilly, GSK, Janssen; Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK, Clovis; Non-Financial Interests, Other, Consultancy: AstraZeneca. F. Rojo: Financial Interests, Personal, Advisory Board: Roche, MSD, BMS, Novartis, AstraZeneca, Daiichi Sankyo, GSK; Financial Interests, Personal, Invited Speaker: Merck. All other authors have declared no conflicts of interest.
Resources from the same session
780P - Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
Presenter: Heidelinde Fiegl
Session: Poster session 11
781P - Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients
Presenter: Janneke Walraven
Session: Poster session 11
782P - Correlation between chemotherapy response score (CRS) and germline BRCA1/2 (gBRCA) status in women diagnosed with FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Presenter: Daniel Netto
Session: Poster session 11
783P - The role of JARID1B in ovarian cancer
Presenter: Katharina Leitner
Session: Poster session 11
784P - HPV integration promotes HPV carcinogenesis via remodeling chromatin interactions between universal stripe factors and super-enhancer in HPV-related carcinoma
Presenter: Canhui Cao
Session: Poster session 11
785P - The predictive role of circulating exosomal PD-L1 in cervical cancer immunotherapy
Presenter: Wenjie Tang
Session: Poster session 11
786P - Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
Presenter: Kosei Hasegawa
Session: Poster session 11
787P - A NGS panel for molecular classification of endometrial carcinoma
Presenter: Hao Wen
Session: Poster session 11
788P - Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
Presenter: Felix Blanc-Durand
Session: Poster session 11
789P - Real-world (RW) duration of treatment in first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC): CHAR1ZMA study
Presenter: Floor Backes
Session: Poster session 11